CL2021000974A1 - Antibacterial polypeptide, composition comprising it and use for treating bacterial infections - Google Patents

Antibacterial polypeptide, composition comprising it and use for treating bacterial infections

Info

Publication number
CL2021000974A1
CL2021000974A1 CL2021000974A CL2021000974A CL2021000974A1 CL 2021000974 A1 CL2021000974 A1 CL 2021000974A1 CL 2021000974 A CL2021000974 A CL 2021000974A CL 2021000974 A CL2021000974 A CL 2021000974A CL 2021000974 A1 CL2021000974 A1 CL 2021000974A1
Authority
CL
Chile
Prior art keywords
composition
polypeptide
bacteria
bacterial infections
treating bacterial
Prior art date
Application number
CL2021000974A
Other languages
Spanish (es)
Inventor
Corsini Acuña Gino
Wiese Plaza Guillermo
Cortés-Cortés Piedad
Manzano Godoy Camila
González Quiñones Samantha
Lagos Moraga Sebastián
Original Assignee
Univ Autonoma De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Autonoma De Chile filed Critical Univ Autonoma De Chile
Priority to CL2021000974A priority Critical patent/CL2021000974A1/en
Publication of CL2021000974A1 publication Critical patent/CL2021000974A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se provee de un polipéptido de SEQ ID NO. 1 denominada como COR- X1 y una composición antibacteriana que comprende este polipéptido, opcionalmente un segundo agente antibacteriano y un vehículo. Esta composición sirve para inhibir el crecimiento y proliferación de bacterias, y en la preparación de un medicamento útil en el tratamiento de afecciones y/o enfermedades provocadas por bacterias. De forma particular, esta composición sirve en la preparación de un medicamento útil en el tratamiento de afecciones y/o enfermedades provocadas por bacterias tanto Gram positivo como Gram negativo, las que se seleccionan del grupo consistente en Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pyogenes, Listeria monocytogenes, Bacillus cereus, Bacillus subtilis, Micrococcus sp.Provided is a polypeptide of SEQ ID NO. 1 designated as COR-X1 and an antibacterial composition comprising this polypeptide, optionally a second antibacterial agent and a carrier. This composition serves to inhibit the growth and proliferation of bacteria, and in the preparation of a medicament useful in the treatment of conditions and/or diseases caused by bacteria. In particular, this composition serves in the preparation of a medicament useful in the treatment of conditions and/or diseases caused by both Gram-positive and Gram-negative bacteria, which are selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pyogenes, Listeria monocytogenes, Bacillus cereus, Bacillus subtilis, Micrococcus sp.

CL2021000974A 2021-04-16 2021-04-16 Antibacterial polypeptide, composition comprising it and use for treating bacterial infections CL2021000974A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2021000974A CL2021000974A1 (en) 2021-04-16 2021-04-16 Antibacterial polypeptide, composition comprising it and use for treating bacterial infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2021000974A CL2021000974A1 (en) 2021-04-16 2021-04-16 Antibacterial polypeptide, composition comprising it and use for treating bacterial infections

Publications (1)

Publication Number Publication Date
CL2021000974A1 true CL2021000974A1 (en) 2022-01-21

Family

ID=80444699

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000974A CL2021000974A1 (en) 2021-04-16 2021-04-16 Antibacterial polypeptide, composition comprising it and use for treating bacterial infections

Country Status (1)

Country Link
CL (1) CL2021000974A1 (en)

Similar Documents

Publication Publication Date Title
Ülkür et al. Comparison of silver-coated dressing (Acticoat™), chlorhexidine acetate 0.5%(Bactigrass®), and fusidic acid 2%(Fucidin®) for topical antibacterial effect in methicillin-resistant Staphylococci-contaminated, full-skin thickness rat burn wounds
IL235526B2 (en) Biofilm prevention, disruption and treatment with bacteriophage lysin
Al Atya et al. Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation
RU2014149351A (en) BACTERIOPHAGE LYSINE COMBINATIONS AND ANTIBIOTICS AGAINST GRAM-POSITIVE BACTERIA
RU2011130278A (en) NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF GRAM-POSITIVE INFECTIONS
JP2012513467A5 (en)
JP2011529898A5 (en)
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
JP2017519730A5 (en)
Gunjan et al. A comparative study of the effect of different topical agents on burn wound infections
RU2020128276A (en) MODIFIED PlySs2 LYSINS AND THEIR APPLICATIONS
HRP20200195T1 (en) Water buffalo derived peptide antibiotic therapies
WO2010041970A3 (en) Antibacterial phage peptides and methods of use thereof
RU2019136978A (en) ANTIBACTERIAL COMPOSITION AND METHOD FOR TREATING STaphylococcal Infections ANTIBACTERIAL COMPOSITION
AR073917A1 (en) ANTIBIOTIC SYNERGISM
BRPI0519942A2 (en) 107891, its a1 and a2 factors, pharmaceutically acceptable salts and compositions and their uses
WO2013041663A3 (en) Modified apidaecin derivatives as antibiotic peptides
MXPA06000691A (en) Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof.
RU2020127327A (en) PATHOGENIC BACTERIA
CL2021000974A1 (en) Antibacterial polypeptide, composition comprising it and use for treating bacterial infections
Baishya et al. Establishment of a simple reproducible model for antibiotic sensitivity pattern study of biofilm forming Staphylococcus aureus
MX2022011291A (en) New recombinant lysin and its use in the treatment of gram-negative bacterial infections.
JP2017533177A5 (en)
KR101818499B1 (en) Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil
CL2021000951A1 (en) Antibacterial polypeptide, composition comprising it and use for treating bacterial infections.